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Currently, there are 19 different peripheral T-cell lymphoma (PTCL) entities recognized
by the World Health Organization; however, ~70% of PTCL diagnoses fall within one of
three subtypes [i.e., peripheral T-cell lymphoma not otherwise specified (PTCL-NOS),
anaplastic large-cell lymphoma, and angioimmunoblastic T-cell lymphoma]. PTCL-NOS
is a grouping of extra-thymic neoplasms that represent a challenging and heterogeneous subset of non-Hodgkin’s lymphomas. Research into peripheral T-cell lymphomas
has been cumbersome as the lack of defining cytogenetic, histological, and molecular
features has stymied diagnosis and treatment of these diseases. Similarly, the lacks of
genetically manipulated murine models that faithfully recapitulate disease characteristics
were absent prior to the turn of the century. Herein, we review the literature concerning
existing mouse models for PTLC-NOS, while paying particular attention to the etiology
of this heterogeneous disease.
Keywords: PTCL-NOS, T-cell lymphoma, mouse models, genetically engineered, neoplasms

MURINE MODELS RECAPITULATING CLINICAL DISEASE
PRESENTATION OF MATURE T-CELL LYMPHOMAS: PTCL-NOS
T-cell malignancies can largely be classified into those affecting precursor T-cells and those affecting
mature, post-thymic T-cells. Peripheral T-cell lymphomas (PTCLs) fall into the latter category and
it is postulated that the cell of origin is an activated, memory cell – most likely a CD44+ T cell.
Importantly, these are potentially cells with self-renewal capacity – a capacity typically only seen in
stem cells, such as hematopoietic stem cells (1–6). There exists some overlap in terms of characteristics of PTCL-NOS and other T-cell lymphomas. For example, PTCL-NOS and angioimmunoblastic
T-cell lymphoma (AITL) bear some similarities in terms of disease presentation, but PTCL-NOS is
distinct from AITL in that AITL cells have solely a follicular T-helper phenotype (PD-1+, CXCL13+)
and PTCL-NOS can include T-cells from differing subtypes (7). PTCLs express monoclonal T-cell
receptor (TCR) or immunoglobulin rearrangement, as well as surface markers of both B- and T-cells
(e.g., BCL-1, BCL-2, and CD20) (8–12). PTCLs are the most aggressive non-Hodgkin Lymphomas,
exhibiting poor response to therapy, and poor prognosis with only 10–30% of patients having longterm survival (10, 13).
Therefore, the need to establish a model system to study this heterogeneous lymphoma subgroup
is warranted. We have included solely genetically manipulated mouse models, as opposed to including xenograft models in immunocompromised mice, to study the impact of disease progression on
the lymphoid compartment as part of the tumor microenvironmental niche. Therefore, we excluded
models that were created without the influence of the immune response, as well as those where
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the B- or T-cell lymphoma were secondary to another disease
driven by carcinogens or genetically engineered into the model.
Similarly, this review does not include models, where PTCLNOS is a secondary neoplasm or a “bystander” development.
Therefore, this review includes the compilation of these models
and the evidence for the potential etiology of PTCL-NOS.
While disease etiology can be exceedingly difficult to discern
since tumors arise well before patients present with symptoms,
murine models of mature T-cell lymphomas (a disease commonly
understudied due to prevalence) are gaining ground because of
their twofold ability to excellently recapitulate human disease and
to point us in the direction of which cell of origin accounts for
the different types of neoplasms. Of the two arms of lymphocytic
lymphomas, B-cells have received the lion’s share of research todate. For the largest type of mature T-cell lymphoma, peripheral
T-cell lymphomas-not otherwise specified (PTCLs-NOS), three
murine models really effectively model human disease. These
models are the following: Snf5−/−, ITK–SYK fusion gene, and
Lin28b.
Various types of animal models to recapitulate leukemias
and lymphomas exist. The impact of such models to mimic
lymphoproliferative diseases were reviewed previously (14). For
this review, we conducted a literature search for murine models
of PTCL-NOS. We conducted a literature search, a search of the
NCI mouse database, Jackson Laboratory’s database, and MGI to
identify all murine models for PTCL-NOS to-date. [A comprehensive summary of T-cell lymphoma murine models is provided
by Warner et al. (15), and murine models of T-cell lymphoma,
including transgenic, viral, carcinogen-induced, oncogene
transformed, knockout, and mosaic models were last reviewed
by Cook and Pardee (16)]. Prior reports of individual models
capture the benefits and limitations of using mouse models to
study lymphoma. Herein, we reviewed the models of PTCL-NOS
in the last 15 years that mimic clinical presentation, disease severity, and genetic profiles common among patients.

mice led to rapid onset PTCL (at ~11 weeks of age) (4, 11, 19).
Mice with a functional TCR died at a mean age of 25 weeks,
whereas those without a functional TCR (Rag−/−) lived past
50 weeks without any sign of tumor (11). CD4-Cre Snf5fl/fl and
Lck-Cre Snf5fl/fl mice developed monoclonal or oligoclonal TdT−,
TCR+, CD3+, CD8+, CD4− mature PTCLs in spleen, liver, and
lymph node (though not thymus – since memory, rather than
early stage T-cells were affected) (11). CD2-Cre Snf5fl/fl mice did
not develop tumors (11). Furthermore, CD44 serves as a marker
of memory phenotype and self-renewal capabilities on CD8+
memory T cells (3, 20). CD44hi Snf5−/− cells were able to give
rise to spontaneous tumors, whereas CD44lo were unable to do
so. These CD44hi memory T cells were observed before tumor
development, thereby implicating them as the potential cell of
origin. Of total lymphoma cells in Snf5 conditional knockout
mice, 15% expressed the CD44hi phenotype.
Most importantly, Wang et al. aimed to determine whether
tumorigenesis in this model was dependent upon TCR signaling
(11). Brg1 is part of the ATP-dependent chromatin remodeling complex SNF/SWI and regulates the expression of CD44.
Specifically, loss of Brg1 results in alterations in T cell development that is nearly identical to those caused by Snf5−/−, but
lymphoma never forms from loss of Brg1. Therefore, there is a
strong correlation between the enrichment of memory phenotype
in the absence of Snf5 and tumorigenesis. Consequently, to investigate tumorigenesis with TCR involvement, CD4-Cre Brg1fl/fl
mice were used and did not give rise to CD44hi memory T cells.
Both Myc and stem cell-like profiles are enriched with loss of Snf5
and these are dependent upon TCR expression (11); specifically,
Lck-Cre Snf5fl/fl Rag2−/− mice do not develop lymphoma. To that
end, Eμ-tTA/tetO-MYC mice developed T cell lymphomas that
can regress upon turning off Myc expression (21). Based on these
data, tumorigenesis in a mature T-cell subtype is dependent upon
TCR signaling (11). These data build upon other murine models
with overexpression of the Myc transgene in hematopoietic cells
– thus giving rise to both T-cell lymphomas and acute myeloid
leukemias (21).
Moreover, after gene set enrichment analyses, Wang et al.
identified 34 differentially expressed genes unique to CD44hi
cells that were downregulated in the non-tumorigenic CD44lo
population. Importantly, some of these genes (ID2, CD44, and
CTLA2A) have already been identified, as playing critical roles
in T-cell lymphomas (22–25), though previously their ability to
contribute to the stem cell phenotype of these cancer cells was
unknown. Therefore, Snf5−/− oncogenesis is dependent upon
TCR signaling. These data shed light onto the role and impact of
the TCR in T cell lymphoma.

Loss of Tumor Suppressor Snf5
Leads to Aggressive PTCL

In an effort to recapitulate human PTCL, Wang et al. created in vivo
models based on the tumor suppressor, Snf5, and determined
the role of the TCR in tumorigenesis. SNF5 is located at 22q11
and is deleted in 50% of T prolymphocytic leukemias, thereby
suggesting its role as a tumor suppressor [(11, 17, 18); Table 1].
Specifically, a Snf5-deficient lymphoma cell line was generated
by three sequential adoptive transfers of CD8+ splenocytes from
Lck-Cre GFP+ Snf5fl/fl tumor-bearing mice and was transplanted
into sublethally irradiated C57BL/6J mice. Snf5 inactivation in

Table 1 | Summary of murine models of T-cell lymphomas.
Gene manipulated

TS or oncogene

Chr(hum)

T-cell subtype affected

Functional pathway

% penetrance

Reference

Snf5−/−
ITK–SYK
Lin28b

TS
Oncogene
Oncogene

Ch22
t(5;9)(q33;q22)a
6q21

Mature, activated memory
Mature, activated memory
Mature, activated memory

Self-renewal
TCR signaling
Let-7 miRNA signaling

100
100
100

(11,17, 18)
(13)
(34)

TS, tumor suppressor; Chr, chromosome; Hum, human.
a
PTCL-NOS with follicular growth is observed in human cases with this translocation.
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ITK–SYK Fusion Kinase
Recapitulating PTCL

engineered mice that can be bred subsequently to generate the
phenotype in next generations.

In human PTCL, the recurrent translocation 5(5;9)(q33;q22)
results in a fusion kinase ITK–SYK that is inducible by interleukin-2. Additionally, 90% of PTCL cases have constitutive
activation of SYK (26). The ITK–SYK complex associates with
lipid rafts and triggers antigen-independent phosphorylation of
proteins near the TCR, including CD69 (i.e., the phenotype of an
activated T-cell) (13). SYK is part of the SYK/ZAP-70 family of
non-receptor kinases modulating the TCR, Fc receptors on mast
cells and macrophages, and BCR signaling (27–30). Moreover,
SYK is present in immature T-cells and is downregulated upon
selection of CD4+ and CD8+ cells (31–33). ITK and SYK
are needed for APC: T cell interaction and subsequent T-cell
activation.
Therefore, Pechloff et al. (13) created a ITK–SYK fusion
kinase model that recapitulates PTCL. Interestingly, this model
essentially functions to constitutively activate antigen–receptor
expression or “mock TCR signaling,” and thereby drive PTCL.
This suggests that the cells involved are antigen-experienced,
and have an activated phenotype, consistent with human cases
and further suggesting a cell of origin, even though ITK–SYK
expression was detected in double positive T-cells during positive
selection in the CD4-Cre ITK–SYK model (13) (Table 1).
The phenotype of the mice bearing this fusion oncogene mimicked that of clinical presentation of PTCL-NOS. Specifically,
these mice had splenomegaly with ITK–SYK expressing TCR-β+
T-cells with an activated phenotype (CD44+), histologically the
splenic architecture was abnormal and infiltrated by medium- to
large-sized lymphocytes, and had increased cellular proliferation.
The bone marrow in all animals was affected, and metastases were
detected in kidney, liver, and lung and these were largely monoclonal, as assessed by TCR-Vβ analyses via flow cytometry and
PCR (13). Interestingly, the expansion of lymphocytes was not
limited to CD4; rather, 61% of animals had abnormal T cells that
were CD4+, but 23% were CD8+, and the rest were double positive (CD4+ CD8+). Such a model may recapitulate extranodal
T-cell lymphomas, such as subcutaneous panniculitis-like T cell
lymphomas and enteropathy-associated T-cell lymphoma, best.
Similarly, Dierks et al. (30) created a murine model of PTCL
using transplanted cells infected with a retrovirus carrying the
ITK–SYK fusion gene (pMSCV ITK–SYK/IRES/GFP). Bone
marrow of sublethally irradiated Balb/c mice was infected with
either the fusion gene-containing vector or GFP-only vector.
PTCL was observed infiltrating LNs, BM, and skin in under a
month, systemic inflammation, increased IL-5 and IFNgamma
production, and tumor cells (ITK–SYK+ T cells) were resistant
to apoptosis. Interestingly, the disease was treatable with SYK
inhibitors (though a search of current Clinical Trials at the time
of writing this review produced no current trials using SYK
inhibitors against lymphoma). This model was dissimilar to
human presentation in that it lacked Bcl6 expression and CD10
was only in trace amounts (~10% of cells) (30). While, these mice
did suffer from PTCL, the ability of this model to replicate human
disease lacked in a few areas, as mentioned above. Moreover,
these mice are laborious to maintain as compared with genetically
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Transgenic Mice Overexpressing Lin28b
Develop PTCL-NOS

LIN28B, a master regulator of cellular transformation, is commonly upregulated in PTCL ~7.5-fold to that of control, activated
CD4+ cells (34) and controls the let-7 family of microRNAs.
Hematopoietic compartment-specific, Lin28b transgenic mice
have a similar disease profile to that of human PTCL. Specifically,
infiltration of parenchymal organs with CD4+ tumor cells,
inflammation, increased C-reactive protein, release of inflammatory cytokines, pleural effusion, and peripheral blood lymphopenia. The lymphopenia involved both CD4+ and CD8+ cells, with
an expansion of tumorigenic CD4+ and CD8+ activated CD44+
CD62L− memory cells. These mice developed lymphoma at
~10 months of age – significantly longer than other models
described herein. Similarly to human PTCLs, these tumor cells
overexpressed SYK, had decreased let-7 expression, increased
IL-6 expression, activation of the NF-κB pathway, infiltration by
B-cells, and lymphadenopathy (34) (Table 1).

OTHER MODELS OF PTCL-NOS TO
STUDY IMPACT ON CD8+ CELLS OR
DEVELOPMENTAL QUESTIONS
Other models that demonstrate T-cell proliferation, but
at varying stages of cellular maturity, include the C3H/
He-Tg(LCKprBCL2)36Sjk/J and B6;129S1-Smarcb1tm3Sho/J models. Specifically, the C3H/He-Tg(LCKprBCL2)36Sjk/J mouse
includes the human LCKprBCL2 transgene, which leads to an
increased percentage of cytotoxic T cells after 10 weeks of age and
mice show robust survival following radiation treatment or with
treatment of an anti-CD3 monoclonal antibody (35).
Another model on the B6 and 129 background has a similar
timeline of disease development. The B6;129S1-Smarcb1tm3Sho/J
strain has loxP sites in opposing orientation flanking the targeted
gene with a reversible Cre-mediated conditional null allele. When
crossed with Mx-Cre mice, these mice develop T-cell lymphoma
with early onset of ~11 weeks of age in 100% of mice (19).
Furthermore, Snf5inv/− mice developed the clinical presentation
and histology that matches mature T-cell lymphoma. Interestingly,
complete knockout of Snf5 (or other members of the SWI/SNF
chromatin remodeling complex) is embryonic lethal, though a
single allele present leads to aggressive T-cell lymphoma very
quickly (19).
Finally, the CALM/AF10 fusion gene is found in T-cell acute
lymphoblastic leukemia and malignant lymphoma (as well as
acute myeloid leukemia). The Vav-Cre-CALM/AF10-Tg model
that has pan hematopoietic expression of the transgene exhibit
lymphoma symptoms at 1 year of age, whereas no leukemia
developed when the transgene was directed solely to CD19+
B-cells (36). Dutta et al. suggest that the cell of origin for CALM/
AF10+ leukemias is a stem cell or early progenitor that acquires
additional activation mutations leading to tumorigenesis.
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While, these models recapitulate aggressive T-cell lymphomas
and they have provided critical insight into T-cell biology (and
etiology leading to PTCL), they are more helpful for studying
developmental questions related to PTCL-NOS as compared
with disease progression and potential treatment modalities,
which represent the lionshare of work using murine models for
PTCL-NOS.

are critical to cellular proliferation, but have no direct association
with the TCR or TCR-signaling partners. NOTCH and MYC
serve as potent oncogenes in both B- and T-cell malignancies.
Additionally, MYC modulates NOTCH and vice versa due to
miRNA regulation through miR-30a (39). Models with and without miR-30a result in diffuse large B-cell lymphoma and T-acute
lymphoblastic leukemia (39), thus mimicking human cases.
Therefore, further studies will inform as to the role of miRNAs
in PTCL-NOS.
Moreover, a recent study identified mutations in CD28
(the TCR co-receptor) in PTCLs (40). These data, coupled
with the role the TCR plays in T-cell lymphoma, warrant
investigation of a conditional knockout of CD28 on PTCL
development. The basic biology of CD28 knockout mice
B6.129X1-Cd28tm1Jmg/Mmjax (41) includes inability to generate
germinal centers in the spleen. Similarly, the CD28tm1Jmg mice
show a reduction in cytokine levels and failure to proliferate in
mixed lymphocyte culture (41).
As this review summarizes the murine models to recapitulate
PTCL-NOS to-date, we identify useful models based on time to
disease presentation, differing genetic manipulations to lead to
disease, and resultant phenotypes that bear resemblance to that
observed in humans suffering from PTCL. Moreover, a review of
these models shed light on the potential etiology of PTCL – likely,
this is a mature cell, either single or double positive, and it bears
stem cell-like capabilities to regenerate, even upon passage into
cell culture and following injection into healthy animals.

SUMMARY
Often mouse xenograft models are used to mimic human disease,
though these are poor models for T-cell lymphomas since the
xenografts do not grow well in mice due to the lack of tumor
microenvironment to sustain tumorigenesis. Therefore, either
conditional knockouts or transgenic mice must be used in order
to mimic T-cell lymphoma to study the biological consequences
and eventually determine therapeutic applications useful for the
disease.
While xenograft models for T-cell lymphomas have been difficult to create, Pechloff et al. and Wang et al. demonstrate that the
cells of the models were transplantable into healthy animals with
the original disease recapitulated. Additionally, the expansion of
T-cells observed in all of these models was unique to malignant
T-cells, and led to a decrease in overall healthy T-cells. These data
suggest that the tumor cells replicate at the expense of healthy
T cells, thereby suppressing the immune response and skewing it
toward a more regulatory phenotype.
While all of the models described herein focused on disease
recapitulation through manipulation of a tumor suppressor or
oncogene, another model of aggressive T-cell lymphomas was
created through chronic, low-dose lipopolysaccharide, and fed
an alcohol-containing diet (37). Therefore, despite there being
models centered around genetic mechanisms to drive T-cell
lymphomas, it is very likely that epigenetic factors play a role as
well. Genetically engineered mice prone to T-cell lymphoma such
Eμ-tTA/tetO-MYC (21) and Lck-Tert (38) have also been generated (37). Although these models do not resemble the human
disease phenotype nor affect only lymphoid cells, as the other
models described herein do – likely because Myc and telomerase
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